Charles Schwab Investment Management Inc. Boosts Position in Qiagen (NYSE:QGEN)

Charles Schwab Investment Management Inc. grew its stake in Qiagen (NYSE:QGEN) by 3.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,513 shares of the company’s stock after buying an additional 1,844 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Qiagen were worth $2,621,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of QGEN. GAMMA Investing LLC increased its position in Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares in the last quarter. Toronto Dominion Bank bought a new position in Qiagen during the second quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV boosted its stake in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares during the last quarter. CWM LLC raised its position in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares during the period. Finally, Headlands Technologies LLC raised its position in Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on QGEN. Jefferies Financial Group restated a “buy” rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $51.15.

Qiagen Trading Down 1.2 %

QGEN stock opened at $45.40 on Monday. The stock has a market cap of $10.36 billion, a price-to-earnings ratio of 116.41, a PEG ratio of 3.52 and a beta of 0.35. The business’s 50-day moving average is $43.21 and its 200 day moving average is $43.72. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.